| dc.contributor.author |
Doganay, S |
|
| dc.contributor.author |
Firat, PG |
|
| dc.contributor.author |
Cankaya, C |
|
| dc.contributor.author |
Kirimlioglu, H |
|
| dc.date.accessioned |
2022-03-23T14:46:44Z |
|
| dc.date.available |
2022-03-23T14:46:44Z |
|
| dc.date.issued |
2013 |
|
| dc.identifier.uri |
http://hdl.handle.net/11616/57422 |
|
| dc.description.abstract |
Purpose: To evaluate the effects of resveratrol and bevacizumab on experimental corneal neovascularization. |
|
| dc.description.abstract |
Method: A corneal alkali burn was performed in 62 eyes of 31 male white Vienna rabbits. Resveratrol (group 1), dimethyl sulfoxide (group 2), bevacizumab (group 3) and 0.9% NaCl (group 4) were administered to both eyes of the rabbits by subconjunctival injection for 7 days. Corneal photos were taken at 15 days after alkali injury. Inflammatory index scores and neovascularization areas were calculated. |
|
| dc.description.abstract |
Results: In bevacizumab group both inflammatory index scores and the calculation of the corneal neovascularization area was significantly less than the groups. |
|
| dc.description.abstract |
Conclusion: The subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit corneal alkali burn model. No effect of resveratrol to the corneal neovascularization on experimental model of the corneal alkali burn was seen at the doses of usage. (C) 2012 Elsevier Ltd and ISBI. All rights reserved. |
|
| dc.source |
BURNS |
|
| dc.title |
Evaluation of the effects of resveratrol and bevacizumab on experimental |
|
| dc.title |
corneal alkali burn |
|